- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Veritas Genetics Launches $999 Whole Genome And Sets New Standard For Genetic Testing
Veritas Genetics introduced Veritas myGenome, the world’s first whole genome for less than $1,000, including interpretation and genetic counseling. Veritas Genetics first broke the $1,000 genome barrier in 2015 when it made whole genome sequencing available to nearly 5,000 participants in the Personal Genome Project (PGP) at Harvard Medical School.
Veritas Genetics introduced Veritas myGenome, the world’s first whole genome for less than $1,000, including interpretation and genetic counseling. Veritas Genetics first broke the $1,000 genome barrier in 2015 when it made whole genome sequencing available to nearly 5,000 participants in the Personal Genome Project (PGP) at Harvard Medical School.
According to the news:
Veritas Genetics is building a platform that will make it easy for its customers and their healthcare providers to use genetic information throughout their lives, including:
A secure digital report and app to easily refer to and interact with results.
Access to their genome for additional interpretation as health needs evolve and science advances.
On-demand additional genetic counseling via video conferencing.
Lifestyle-relevant genetic information that can be shared with non-clinical service providers such as fitness coaches and nutritionists.
Access to physicians at Massachusetts General Hospital, Dana Farber Cancer Institute, Boston Children’s Hospital, Mayo Clinic, and others for clinical opinions and clinical follow-up care through Veritas Genetics’ partnership with WorldCare International and WorldCare Consortium®.
Integration of other “omics” data sets on a single platform.
Mirza Cifric, CEO and co-founder commented:
The whole genome is the new standard. At this price point, there is no reason to use anything but the whole genome, especially for any tests that are close to or more than the price of our whole genome. The whole genome is the foundation of precision medicine and a lifetime resource to maximize quality of life and longevity.
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.